Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

11 evidence topics · 8 sources

RAPIDe-3 regional subgroups: median times to onset of symptom relief, reduction in attack severity, and complete resolution
Outcome and regionDeucrictibant IRPlacebo
Onset of symptom relief, North America“1.20 hours (95% CI: 0.84, 1.84)”“6.55 hours (95% CI: 1.88, >12)”
Onset of symptom relief, Europe/Rest of World“1.28 hours (95% CI: 1.04, 1.41)”“>12 hours (95% CI: 5.74, >12)”
Reduction in attack severity, North America“2.43 hours (95% CI: 1.03, 5.12)”“>12 hours (95% CI: 2.65, >12)”
Reduction in attack severity, Europe/Rest of World“2.53 hours (95% CI: 1.70, 2.98)”“>12 hours (95% CI: 12.10, >12)”
Complete symptom resolution, North America“11.61 hours (95% CI: 2.94, 26.14)”“>48 hours (95% CI: 17.21, >48)”
Complete symptom resolution, Europe/Rest of World“12.04 hours (95% CI: 8.64, 21.79)”“>48 hours (95% CI: >48, >48)”
Sebetralstat open-label extension: attacks during long-term prophylaxis by severity, location, and age

“In subgroup analyses by attack severity at the time of sebetralstat administration, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 1.8 (1.0-7.0) hours, 1.3 (0.8-3.5) hours, and 1.3 (0.5-1.8) hours for mild, moderate, and severe/very severe attacks, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Subgroup analyses by attack location showed median (IQR) times to beginning of symptom relief in participants receiving any LTP agent of 1.3 (0.7-2.2) hours, 1.4 (0.9-4.1) hours, 1.0 (0.5-2.2), and 1.7 (1.2-6.0) hours for attacks with mucosal involvement, attacks with laryngeal involvement, attacks limited to the abdomen, and attacks limited to subcutaneous tissues, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In subgroup analyses by age, median (IQR) times to beginning of symptom relief in participants receiving any LTP agent were 0.7 (0.3-1.4) hours and 1.7 (1.1-5.5) hours for participants aged <18 years (n = 5) and participants aged ≥18 years (n = 30), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Furthermore, the study was not designed or powered to evaluate differences in the effectiveness of sebetralstat by the specific LTP agent received or differences between subgroups; these data are reported to offer a preliminary clinical overview.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote